Linked Life Data

16406507

Source:http://linkedlifedata.com/resource/pubmed/id/16406507

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16406507rdf:typepubmed:Citationlld:pubmed
pubmed-article:16406507lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:16406507lifeskim:mentionsumls-concept:C0023413lld:lifeskim
pubmed-article:16406507lifeskim:mentionsumls-concept:C0596087lld:lifeskim
pubmed-article:16406507lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:16406507lifeskim:mentionsumls-concept:C1704426lld:lifeskim
pubmed-article:16406507lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:16406507pubmed:issue4lld:pubmed
pubmed-article:16406507pubmed:dateCreated2006-2-17lld:pubmed
pubmed-article:16406507pubmed:abstractTextWe performed a phase I study with the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 combined with 5-fluorouracil and leucovorin (5-FU/LV) to determine safety profile and assess pharmacokinetic interactions. Patients with advanced solid malignancies received LV 20 mg/m(2) followed by 5-FU 425 mg/m(2) both administered intravenously in 15 min daily for 5 days every 4 weeks. ABT-510 was administered subcutaneously twice daily continuously from day 2 onwards. Blood and urine samples for pharmacokinetic analyses were collected at days 1, 5 and 22. Twelve patients received a total of 45 cycles of 5-FU/LV combined with ABT-510. ABT-510 dose levels studied were 50 and 100 mg. The combination was well tolerated, with a toxicity profile comparable to that of 5-FU/LV alone. At the dose levels studied no significant pharmacokinetic interactions were observed. These data indicate that ABT-510 administered twice daily subcutaneously can be safely combined with 5-FU/LV administered daily for 5 days, every 4 weeks.lld:pubmed
pubmed-article:16406507pubmed:languageenglld:pubmed
pubmed-article:16406507pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16406507pubmed:citationSubsetIMlld:pubmed
pubmed-article:16406507pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16406507pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16406507pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16406507pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16406507pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16406507pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16406507pubmed:statusMEDLINElld:pubmed
pubmed-article:16406507pubmed:monthMarlld:pubmed
pubmed-article:16406507pubmed:issn0959-8049lld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:KnightRRlld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:CarrR ARAlld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:GietemaJ AJAlld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:VerweijJJlld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:HoekstraRRlld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:Humerickhouse...lld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:de VriesE G...lld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:EskensF A L...lld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:UgesD R ADRlld:pubmed
pubmed-article:16406507pubmed:authorpubmed-author:de VosF Y F...lld:pubmed
pubmed-article:16406507pubmed:issnTypePrintlld:pubmed
pubmed-article:16406507pubmed:volume42lld:pubmed
pubmed-article:16406507pubmed:ownerNLMlld:pubmed
pubmed-article:16406507pubmed:authorsCompleteYlld:pubmed
pubmed-article:16406507pubmed:pagination467-72lld:pubmed
pubmed-article:16406507pubmed:dateRevised2008-6-5lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:meshHeadingpubmed-meshheading:16406507...lld:pubmed
pubmed-article:16406507pubmed:year2006lld:pubmed
pubmed-article:16406507pubmed:articleTitlePhase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.lld:pubmed
pubmed-article:16406507pubmed:affiliationDepartment of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, The Netherlands. r.hoekstra@zgt.nllld:pubmed
pubmed-article:16406507pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16406507pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16406507pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16406507pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16406507lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16406507lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16406507lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16406507lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16406507lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16406507lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16406507lld:pubmed